These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39004987)

  • 21. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
    Roset M; Amonkar M; Patel R; Lara N; Kothari S
    Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with the initiation of chemotherapy within 90 days of death in metastatic colorectal cancer patients: a population-based study.
    Batra A; McKinnon G; Billawala A; Sheka D; Kong S; Cheung WY
    Support Care Cancer; 2021 Mar; 29(3):1535-1542. PubMed ID: 32725376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer.
    McLean J; Rho YS; Kuruba G; Mamo A; Gilabert M; Kavan T; Panasci L; Melnychuk D; Batist G; Kavan P
    Clin Colorectal Cancer; 2016 Jun; 15(2):135-40. PubMed ID: 26553578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?
    Au L; Turner N; Wong HL; Field K; Lee B; Boadle D; Cooray P; Karikios D; Kosmider S; Lipton L; Nott L; Parente P; Tie J; Tran B; Wong R; Yip D; Shapiro J; Gibbs P
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e167-e174. PubMed ID: 28299879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line treatment choices of Turkish medical oncologists in metastatic colorectal cancer: A survey study.
    Beypinar I; Araz M; Uysal M; Yalcin S
    J BUON; 2019; 24(1):68-76. PubMed ID: 30941953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!
    Moehler M; Thomaidis T; Zeifri C; Barhoom T; Marquardt J; Ploch P; Schattenberg J; Maderer A; Schimanski CC; Weinmann A; Woerns MA; Kranich AL; Warnecke JM; Galle PR
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):515-22. PubMed ID: 25230900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.
    Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Kuijf HJ; Punt CJA; Koopman M; May AM
    J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):909-919. PubMed ID: 30144305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns for metastatic colorectal cancer in Spain.
    Aranda E; Polo E; Camps C; Carrato A; Díaz-Rubio E; Guillem V; López R; Antón A
    Clin Transl Oncol; 2020 Sep; 22(9):1455-1462. PubMed ID: 31974819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.
    Sorbye H; Pfeiffer P; Cavalli-Björkman N; Qvortrup C; Holsen MH; Wentzel-Larsen T; Glimelius B
    Cancer; 2009 Oct; 115(20):4679-87. PubMed ID: 19562777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF
    Gourdin G; Chotel L; de la Fouchardière C
    Adv Ther; 2023 Aug; 40(8):3281-3290. PubMed ID: 37316651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.
    Ivanova JI; Saverno KR; Sung J; Duh MS; Zhao C; Cai S; Vekeman F; Peevyhouse A; Dhawan R; Fuchs CS
    Med Oncol; 2017 Nov; 34(12):193. PubMed ID: 29103187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
    Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
    [No Abstract]   [Full Text] [Related]  

  • 33. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
    BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Utilization, Barriers, and Factors Associated With the Targeted Treatment of Metastatic Colorectal Cancer Patients in China: A Multi-Center, Hospital-Based Survey Study.
    Liu Y; Zhang X; Xu HF; Shi JH; Zhao YQ; Du LB; Liu YY; Wang WJ; Cao HL; Ma L; Huang JX; Cao J; Li L; Fan YP; Gu XF; Feng CY; Zhu Q; Wang XH; Du JC; Zhang JG; Zhang SK; Qiao YL
    Int J Public Health; 2023; 68():1606091. PubMed ID: 37465051
    [No Abstract]   [Full Text] [Related]  

  • 35. Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia.
    Turner NH; Wong HL; Field K; Wong R; Shapiro J; Yip D; Nott L; Tie J; Kosmider S; Tran B; Desai J; McKendrick J; Zimet A; Richardson G; Iddawela M; Gibbs P
    Asia Pac J Clin Oncol; 2015 Sep; 11(3):262-71. PubMed ID: 25871458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment.
    Ge P; Wan N; Han X; Wang X; Zhang J; Long X; Wang X; Bian Y
    Front Pharmacol; 2022; 13():914683. PubMed ID: 36110513
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer.
    Baek SK; Lee KT; Bae SB; Lee SC
    Korean J Intern Med; 2019 Nov; 34(6):1188-1196. PubMed ID: 31346151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion.
    Fernández-Montes A; Grávalos C; Pericay C; Safont MJ; Benavides M; Élez E; García-Alfonso P; García-Paredes B; Carrato A; Aranda E
    Clin Colorectal Cancer; 2020 Sep; 19(3):165-177. PubMed ID: 32507561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry.
    Chong LC; Hardingham JE; Townsend AR; Piantadosi C; Rico GT; Karapetis C; Padbury R; Maddern G; Roy A; Price TJ
    Target Oncol; 2020 Dec; 15(6):751-757. PubMed ID: 33068283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.
    Trojan J; Mineur L; Tomášek J; Rouleau E; Fabian P; de Maglio G; García-Alfonso P; Aprile G; Taylor A; Kafatos G; Downey G; Terwey JH; van Krieken JH
    PLoS One; 2015; 10(10):e0140717. PubMed ID: 26491871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.